Posted On: 03/10/2016 11:35:02 AM
Post# of 72446
Will someone refresh my poor memory on share price valuation:
What is the biotech industry standard for multiples of projected revenue which the share price typically is at? I seem to recall distant past discussions of 4x by legitimate posters on the other site.
So just for the sake of argument if CTIX has roughly 150m outstanding shares and the share price is $180 pps, then the company should be valued at roughly $27b, correct? The would mean that the market or the BP partner will be expecting the drugs to net around $6-7b in revenues a year? Am I thinking about this correctly? That seems high, so what am I missing?
What is the biotech industry standard for multiples of projected revenue which the share price typically is at? I seem to recall distant past discussions of 4x by legitimate posters on the other site.
So just for the sake of argument if CTIX has roughly 150m outstanding shares and the share price is $180 pps, then the company should be valued at roughly $27b, correct? The would mean that the market or the BP partner will be expecting the drugs to net around $6-7b in revenues a year? Am I thinking about this correctly? That seems high, so what am I missing?
(0)
(0)
